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Abstract
The Ebola virus disease outbreak in 2014–2015 led to a huge caseload with a high case fatality rate. No specific treat-
ments were available beyond supportive care for conditions such as dehydration and shock. Evaluation of treatment with
convalescent plasma from Ebola survivors was identified as a priority. We evaluated this intervention in an emergency
setting, where randomization was unacceptable. The original trial design was an open-label study comparing patients
receiving convalescent plasma and supportive care to patients receiving supportive care alone. The comparison group
comprised patients recruited at the start of the trial before convalescent plasma became available, as well as patients
presenting during the trial for whom there was insufficient blood group–compatible plasma or no staffing capacity to
provide additional transfusions. However, during the trial, convalescent plasma was available to treat all new patients.
The design was changed to use a comparator group comprising patients previously treated at the same Ebola treatment
center prior to the start of the trial. In the analysis, it was planned to adjust for any differences in prognostic variables
between intervention and comparison groups, specifically baseline polymerase chain reaction cycle threshold and age. In
addition, adjustment was planned for other potential confounders, identified in the analysis, such as patient presenting
symptoms and time to treatment seeking. Because plasma treatment started up to 3 days after diagnosis and we could
not define a similar time-point for the comparator group, patients who died before the third day after confirmation of
diagnosis were excluded from both intervention and comparison groups in a per-protocol analysis. Some patients
received additional experimental treatments soon after plasma treatment, and these were excluded. We also analyzed
mortality including all patients from the time of confirmed diagnosis, irrespective of whether those in the trial series
actually received plasma, as an intention-to-treat analysis. Per-protocol and intention-to-treat approaches gave similar
conclusions. An important caveat in the interpretation of the findings is that it is unlikely that all potential sources of con-
founding, such as any variation in supportive care over time, were eliminated. Protocols and electronic data capture sys-
tems have now been extensively field-tested for emergency evaluation of treatment with convalescent plasma. Ongoing
studies seek to quantify the level of neutralizing antibodies in different plasma donations to determine whether this influ-
ences the response and survival of treated patients.
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Introduction
At the onset of the outbreak of Ebola virus disease in
West Africa in 2014, patients received supportive care
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(e.g. treatment for dehydration and shock), but no spe-
cific treatments had been shown to reduce the very high
case fatality rate. Transfusing convalescent whole blood
or plasma from patients who had survived and recov-
ered to those with active disease had been a strategy
used successfully to treat other infectious diseases.1,2
Such blood transfusions were used for eight patients in
the Kikwit Ebola outbreak. Although seven survived, it
was not clear whether their survival was attributable to
the transfusions.3 Evaluation of convalescent plasma
for the treatment of Ebola disease was identified as a
priority by the World Health Organization (WHO) in
September 2014,4,5 as the treatment, if safe and effec-
tive, could be a relatively low-cost intervention that
could be scaled up relatively quickly.6,7
In September 2014, the Ebola epidemic in West
Africa appeared to be out of control, with large num-
bers of patients presenting for treatment and case fatal-
ity rates of around 70%.8 Ebola treatment centers were
overwhelmed and there were alarming rates of trans-
mission to healthcare staff.9,10 The urgency of develop-
ing and evaluating better treatments for the disease was
recognized by funding agencies and support was made
available to study treatments. Several international
meetings were held to discuss not only which therapeu-
tic interventions should be prioritized in clinical trials
but also the trial design options that would be ethically
and scientifically acceptable.11 A consortium of
European and Guinean collaborators was rapidly
formed and a protocol developed to conduct a trial of
convalescent plasma in a treatment center run by
Me´decins Sans Frontie`res (Doctors without Borders) in
Guinea. Funding was awarded for the trial to the
‘‘Ebola_Tx’’ consortium by the European Union on 5
October 2014.
Using the WHO guidance on plasma treatment of
Ebola disease,12 the protocol for the Ebola_Tx trial
sought to balance scientific rigor in design and conduct,
with what could be achieved in the challenging field
conditions. The trial was designed to be as inclusive as
possible so that the design would be ethically acceptable
to the concerned community and the results would be
widely applicable. Patients of all ages were eligible,
including pregnant women and infants. Scientifically,
the optimal design would have been some form of ran-
domized controlled trial, preferably blinded, with a par-
allel arm of patients not receiving convalescent plasma.
However, local authorities and field partners in Guinea
indicated that a randomized trial including a control
arm was unacceptable in the volatile settings of the
expanding Ebola outbreak. Another constraint on the
design of the trial was that the number of additional
blood samples to be taken during the trial was mini-
mized to reduce risks to patients and staff and to ensure
that limited clinical resources were not diverted from
providing care to patients. As Ebola survivors are a
stigmatized and vulnerable population, specific
anthropological studies were necessary to investigate
attitudes to blood and plasma donations and the use of
such donations in treatment.13–15
Ethical clearance was sought from the national
ethics committee in the study country (Guinea), the
Institutional Review Board of the sponsor (Institute of
Tropical Medicine, Belgium) the Ethics Committee of
the University of Antwerp and those of the collaborat-
ing partner institutions—Me´decins Sans Frontie`res,
WHO and the London School of Hygiene and Tropical
Medicine. The protocol was also reviewed by the scien-
tific commission of the National Ebola Coordination in
Guinea. Initial submissions were made on 4 December
2015, and all approvals were obtained by 26 January
2015. The collection of plasma donations from recov-
ered consenting Ebola survivors began on 9 February
2015 and plasma transfusion to Ebola patients on 19
February 2015.
In this article, we discuss challenges in the design
and analysis of this trial and several modifications that
had to be made to adapt to changing circumstances
during the course of the trial. Findings are summarized
elsewhere.
Hypothesis and outcomes of interest
The main objective of the trial was to determine
whether treatment with convalescent plasma would
reduce the case fatality rate of Ebola patients. All
Ebola patients admitted to the treatment center before
and during the trial period received supportive care.
The trial was designed to have statistical power to
detect an absolute risk reduction in mortality of at least
20% associated with plasma treatment. The choice of
20% was debated by international experts during a
series of teleconferences organized by WHO. It was
considered that a mortality reduction of this magnitude
would be required to justify the potential risks to
healthcare staff, the significant investment in infrastruc-
ture and the commitment of scarce resources that
would be necessary to provide widespread access to
plasma treatment. Secondary analyses and outcomes
included the change in viral load after plasma adminis-
tration, the correlation of survival with antibody levels
in the donor plasma, the incidence of adverse transfu-
sion reactions and any hazards to staff in administering
plasma. An overview of the trial is given in Table 1.
Intervention
In therapeutic drug trials, the dosage of the supposed
active ingredient is generally specified and standardized
for patients. The presumed mode of action of convales-
cent plasma is through the presence of neutralizing
antibodies in donor plasma. Antibody levels vary from
donor to donor; ideally, we would have selected plasma
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donations with high antibody levels. However, this
required shipment of samples abroad to conduct assays
for levels of neutralizing antibodies in a high contain-
ment laboratory, which entailed long delays.
Consequently, we chose to use the WHO-recommended
procedure to transfuse two units of 250 mL of plasma
not assayed for neutralizing antibodies, each from a
different donor, as soon as possible after a confirmed
diagnosis of Ebola. All patients in the study were trans-
fused within 3 days of diagnosis.
Study design
There was much debate about the need for randomiza-
tion to an experimental treatment or control group to
ensure the most scientifically rigorous evaluation. This
debate was happening at the same time as expatriates
from high-income countries who were infected with
Ebola were being evacuated from the epidemic areas
and treated in North America and Europe with experi-
mental therapies, outside of controlled trials. In these
circumstances, the acceptability of a control arm, in
which some patients would receive only supportive
care, was challenged for a condition known to have a
very high mortality rate. Our own enquiries in Guinea,
and those of others, indicated that a randomized trial
with a control arm would not be accepted.16 We note
that a randomized clinical trial was started in Guinea
in another Ebola Treatment Unit in July 2015.17
The original plan for the trial was a non-randomized
parallel group design whereby control patients treated
with supportive care alone would be recruited at the
start of the trial, while a team worked with survivors
and the national blood transfusion service to set up the
facilities and to recruit the donors necessary to supply
plasma donations. In addition, it was planned that
patients not receiving plasma treatment during the trial,
because of the lack of blood group–compatible plasma,
limited capacity in the treatment center to administer
plasma to multiple patients simultaneously or a refusal
to receive plasma, would also be enrolled as controls
(Figure 1(a)).
Eligibility for inclusion in the trial, for
receipt of plasma and patient
prioritization
All confirmed cases presenting at the treatment center
were to be assessed for eligibility to receive plasma, pro-
vided consent was given, including children and preg-
nant women. The only patients to be excluded were
those with contraindications to plasma treatment, those
with very advanced disease (too late to be likely to be
influenced by plasma treatment) or agitated patients
for whom administration of plasma might be hazar-
dous to staff (Table 1).
During preparation for the study, when the caseload
was very high, it was anticipated that operational con-
straints (insufficient plasma or treatment capacity)
would restrict the number of patients who could be
treated. Therefore, it was necessary to set up an algo-
rithm to determine which patients would be prioritized
for plasma treatment. Allocation had to be done in a
way that was perceived as fair to patients and staff but
without introducing bias in assessing the impact of the
treatment on survival rates. Criteria for prioritization
had to be manageable (taking into account the current
practices at the laboratory and treatment centers),
acceptable (for patients, their family and caregivers)
and allow maximal potential benefit of treatment.
There was consideration of selecting eligible patients
according to their clinical status, such that patients with
Table 1. Overview of the Ebola_Tx trial.
Main funder European Union
Sponsor Institute of Tropical Medicine, Antwerp
Study site Conakry, Guinea
Study design/phase Phase III, non-randomized, comparative study
Inclusion criteria Confirmed Ebola virus disease—all ages, including pregnant women and infants
Exclusion criteria for receipt
of convalescent plasma
History of allergic reaction to blood or blood products
Medical condition that precludes transfusion (e.g. decompensated heart failure)
Patients arriving in a close to terminal condition
Conditions that would jeopardize the safety of treating staff (e.g. agitated patient)
Intervention Two units of convalescent plasma given consecutively (adults: 2 3 200–250 mL;
children: total 10 mL/kg), with each unit from a different donor
Titers of neutralizing antibodies were not known at time of administration
(unselected convalescent plasma)
Primary outcome Survival at 14 days post administration of convalescent plasma
Secondary outcomes Survival at 30 days
Serious adverse reactions
Change in viral load after convalescent plasma treatment
Safety risks in health workers
Risk factors for mortality
Edwards et al. 15
 at University of Liverpool on February 2, 2016ctj.sagepub.comDownloaded from 
characteristics known to indicate a poor prognosis
would be prioritized. These included patients with signs
of shock, pregnant women and children less than
5 years of age. However, this plan was not pursued, as
evaluation of plasma treatment would be challenging
or impossible with such prioritization, and such selec-
tion may have biased against detecting any beneficial
effect. ‘‘First come, first served’’ was the preferred
approach, after several discussions with the different
stakeholders, as the only allocation method accepted as
fair. However, if plasma was in short supply, then a
queuing system for treatment might have led to patients
being treated some days after diagnosis, at a time when
plasma might have little effect. Therefore, to avoid
accumulating patients on a waiting list, a 48-h window
of intervention after diagnosis was added to the priori-
tization algorithm. For example, suppose Patient 1 was
diagnosed on day 1 at 3 p.m., but no compatible
plasma was available. Patient 2 was diagnosed on day 2
at 11 a.m. and had the same blood group. If sufficient
compatible plasma for one patient became available on
day 2 at 4 p.m., Patient 1 would be the one treated.
However, if compatible plasma were only to be
available on day 3 at 6 p.m. (.48 h after Patient 1’s
diagnosis), the available plasma would be given to
Patient 2.
By the time recruitment began, with the declining
epidemic, there was sufficient plasma available to treat
all eligible patients and prioritization was unnecessary.
Sources of comparative data for analysis
Enrolled patients meeting any of the clinical exclusion
criteria for plasma treatment (Table 1) received suppor-
tive care and were not to be included in comparative
analysis. The ‘‘control’’ patients to be included in com-
parative analysis were those patients who
 Would be eligible for, but refused, plasma treatment;
 Did not receive plasma treatment due a lack of
availability of blood group–compatible plasma,
either at the start of the study before plasma
became available or as recruitment was ongoing
once there was a supply of plasma;
 Did not receive plasma due to a lack of clinical
capacity to administer the treatment.
A lack of compatible plasma would have been
dependent on blood group, which was thought unlikely
to be associated with survival and therefore would not
introduce bias between comparison groups.
By the time trial recruitment could begin, a large
number of willing donors were available and, as Ebola
case numbers were falling, the supply of plasma
matched the need. Although there was a provision in
the original protocol to include data on patients treated
at the same treatment center before the start of the
trial, to complement concurrent control data in the
event that very few control patients following the start
of the trial, a protocol amendment was approved to use
historic data from patients treated before the trial from
the same treatment center as the patients treated with
plasma as part of the trial (Figure 1(b)).
Sample size
When the trial was designed, reports of mortality rates
varied substantially between Ebola treatment centers.
We did not have information on the rate in the treat-
ment center where the trial would be conducted, and
we therefore calculated the required sample size under
assumptions of 90% power, a two-sided alpha of 0.05
and an absolute risk reduction of 20%, for a range of
mortality rates. We expected that recruitment might
have a ratio of 2:1 for plasma-treated and comparator
patients, based on caseload reports. Two hundred
plasma-treated patients (and 100 comparator patients)
would provide 90% power, if mortality in comparator
patients was in the region of 40%–80%. In the event of
Figure 1. (a) Planned non-randomized design: starting
recruitment under the planned non-randomized design was on
consideration of adequate plasma becoming available with
minimal delay. (b) Implemented design: trial recruitment started
once a minimum stock of plasma was available.
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an equal number of plasma-treated and comparator
patients being recruited, 130 patients per group would
be required to meet the same design assumptions.
As plasma was available for all eligible patients,
there were no concurrent control patients who did not
receive plasma, and we decided that the most appropri-
ate comparison group would be historic patients treated
in the same treatment center from September 2014 until
the start of the trial, during which time 507 confirmed
cases were admitted.
By July 2015, the Ebola epidemic in Guinea had
declined to a low level and few new patients were being
treated. On advice from the Data and Safety
Monitoring Board, given the decline in the epidemic,
recruitment to the study was closed on 7 July 2015. Of
a planned recruitment target of 130 patients, 102
patients had been enrolled. Despite having fewer than
130 patients, the high number of comparator patients
in the historic series meant that the study was still pow-
ered to detect an overall absolute difference in survival
of 20%.
Interim analysis and data and safety
monitoring
No interim analysis stopping rule for overwhelming
efficacy or futility was included in the trial design. If a
benefit of plasma treatment was observed early in the
trial, it was planned that plasma administration to new
patients would continue as it was of interest to continue
data collection to narrow the confidence interval on the
effect of the treatment and to gather further data for
complementary analyses of antibody titers, changes in
viral load and survival. No formal stopping rule for
harm was included either, as the Data and Safety
Monitoring Board met regularly to review cumulative
survival data and serious adverse reaction reports.
The rapidly changing Ebola epidemic and simulta-
neous evaluation of treatments by different consortia in
other Ebola treatment centers meant that the investiga-
tors and the Data and Safety Monitoring Board faced
many uncertainties. The Board mandate allowed rec-
ommendations to stop the trial in various circum-
stances, such as if the feasibility of plasma treatment
became unsustainable due to a shortage of plasma or
because of negative perceptions of patients, staff,
donors or the local community. The Board was also
charged to review the changing environment of the
Ebola epidemic in terms of caseload and recruitment
rates and the possibility of additional treatment options
being shown to be effective in other studies so that they
might advise on possible changes to supportive care
(e.g. addition of antivirals) and necessary adaptations
to the design and sample size.
Importantly, when the trial was started, it was not
anticipated that measuring antibodies in donated
plasma would be significantly delayed due to adminis-
trative and logistic issues. It was recognized that the
level of neutralizing antibody levels in donated plasma
could not be measured prior to transfusion, but it was
anticipated that these would become available later
after shipping and laboratory testing in Europe. It was
planned that the Data and Safety Monitoring Board
would review data on donor plasma antibody levels
and patient survival and could potentially recommend
a change to the design of the trial, such as restricting
plasma donations to those with higher neutralizing
antibody levels. These data were not available before
the Board recommended an end to trial entry.
Blinding of staff and patients was not possible, but it
was planned that investigators and staff would be blind
to the summary survival status of patients entered into
the trial, although, of course, there was much interest in
patient outcomes. This summary information was pro-
vided only to the Data and Safety Monitoring Board.
Cumulative survival data of patients in the trial and in
the historic series were reported to the Board on a regu-
lar basis for the primary analysis population. One sta-
tistician was unblinded to prepare these results, but
investigators remained blind until after the Board rec-
ommended to stop recruitment. The only way of keep-
ing staff and investigators blind to the treatment given
would have been to have included a control arm in
which patients were transfused with plasma not derived
from convalescent patients. While this option was con-
sidered at the design stage of the trial, it was rejected on
largely ethical grounds (but also because of acceptabil-
ity and logistic issues) in that it was thought there was
insufficient scientific evidence that normal plasma
would offer benefit and it would subject patients to an
unnecessary procedure and staff to the potential
hazards of administering the plasma.
Sources of bias, analytical approach and
limitations in context
It is widely acknowledged that a lack of randomization
and use of historic controls can lead to treatment
groups that are unbalanced with respect to important
measured and unmeasured confounding factors that
may bias comparative analyses. If, for example, the
mortality rate declined during the course of the epi-
demic, comparison of the survival of recently treated
patients with a historic comparison group could lead to
a misleading conclusion of benefit of plasma treatment,
or an increased mortality risk associated with plasma
treatment might be masked.
We considered potential for bias and how to obtain
comparable analysis groups in detail (Table 2). We
sought to minimize the potential bias in the use of his-
toric controls by adjusting comparative analyses for
factors that are known to influence survival, including
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Table 2. Sources of bias, analytical approach and limitations in context using historic controls as the comparison group
Possible source
of bias
Problem Analytical approach in the
analysis plan to reduce bias
Implications
Survival bias Definition of a comparable
starting point for follow-up for
both groups:
PCR confirmation of diagnosis
may not be received on the
same day the sample was taken;
Upon confirmation of diagnosis,
plasma treatment could be
initiated on that day or up to
2 days later;
A comparable date for starting
plasma treatment could not be
defined for historic control
patients who were not assessed
for eligibility to receive
convalescent plasma.
Exclude deaths occurring up to
and including the second day
after confirmation of Ebola virus
disease diagnosis.
Patients in both groups have a
comparable starting point of the third
calendar day after diagnosis (Figure 2).
Unbiased comparison of convalescent
plasma and historic patients (with
respect to follow-up time). Case
fatality rate underestimated in both
groups as early deaths excluded
(Figure 2), but ‘‘intention-to-treat’’
analysis also performed.
With a starting point of day 3,
survival status 14 days post-
diagnosis may not allow a full
14 days of follow-up after the
onset of treatment in the
convalescent plasma group.
The primary outcome was
measured as survival status
16 days after diagnosis for both
plasma-treated and historic
patients, as plasma
administration started up to
2 days after diagnosis.
Analysis of the primary endpoint
becomes mortality between the 3rd
and 16th days post-diagnosis for a
harmonized follow-up period. Few
deaths from Ebola virus disease were
expected after day 16 in either group.
Patients were discharged once
confirmed cured. In the trial,
patients were contacted by
phone to confirm survival status
up to day 30, but this was not
done for the historic patients.
Assume historic patients
discharged confirmed cured
before day 16 were alive at
day 16.
It is possible that deaths between days
16 and 30 could be missed for historic
patients, but these would likely be due
to concomitant conditions or possible
sequelae and occur very rarely. One
death occurred between days 16 and
30 in a plasma-treated patient after
being discharged cured of Ebola
disease due to another concomitant
condition. Comparison of mortality
rates was confined to day 16 only.
Patients still hospitalized on day
16 are counted as survivors in
the primary analysis.
Measurement
bias and
residual
confounding
Accurate data capture was
expected for objective factors
such as age, sex and PCR cycle
threshold as an indicator of viral
load.
A priori adjustment for more
objective measures of
prognostic factors of age and
PCR cycle threshold value at
diagnosis, based on available
literature.
Clinical symptom data may be
subjective and there could be
variability in reporting in the two
periods or missing data for historic
series patients if staff had little time for
complete data collection and checking.
Opportunities may have missed to
detect imbalance between groups.
Although the same variables of
interest were being recorded
with similar data collection
forms by the same on-site team
for historic and trial series,
there may have been bias in
capture of clinical symptom data
over time.
Adjust for baseline factors
associated with survival in
historic patients and also found
to be unbalanced between
convalescent plasma and historic
patient groups.
Effects of confounding taken into
account for measured factors, but
limitations remain in case of
measurement error or reporting bias.
Patient symptoms and clinical
characteristics associated with
survival may be imbalanced
between treatment groups
through a real effect or as a
result of reporting bias.
Bias toward better survival in
trial period, either through
better care with additional trial
focus on-site or due to lower
caseload.
Residual bias may be present.
(continued)
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presenting polymerase chain reaction (PCR) cycle
threshold (a measure of viral load) and age. We also
examined the variation in mortality rates by month for
the period September 2014–January 2015. There was
some variation, but our findings were not materially
changed by restricting the period for historic controls
to November–January.
In a randomized trial, the date of start of treatment
is clearly defined for each patient. It was not possible to
start the administration of plasma immediately after the
diagnosis of Ebola, and often there was a delay of a day
or, at most, two in initiating plasma treatment. There
was no way of identifying a similar time-point for
patients in the control series. To overcome this prob-
lem, in the comparative analyses of survival, we consid-
ered survival from the date of Ebola confirmation plus
2 calendar days and then up to 14 days later in both
treated and comparator series (Table 2). Fourteen days
of follow-up would then end on day 16 post-diagnosis.
In the original protocol, we had not anticipated this
issue and had planned to study mortality up to day 14
post-plasma administration. As a consequence, in the
primary analysis, we excluded deaths in both series that
occurred up to day 3 following diagnosis (Figure 2).
This restriction excluded patients who died rapidly after
diagnosis, who generally presented with advanced dis-
ease, in whom it was considered that plasma was
unlikely to influence the course of disease.
We also conducted an intention-to-treat analysis,
including all patients in both series from the time of
confirmed diagnosis, irrespective of whether patients
presenting to the treatment center and confirmed as
having Ebola in the trial series actually received plasma.
Discussion
Randomized controlled trials are the gold standard for
assessing new interventions, and the ideal design would
have been such a trial, with a control arm in which con-
valescent plasma was not administered. In a setting
where randomized trials of treatment were deemed
locally unacceptable, we sought to develop an alterna-
tive design while aiming to minimize bias and con-
founding. We anticipated that we would have a group
of patients for whom blood group–compatible plasma
was not available and we would also have patients who
could not be treated because of other logistic con-
straints. We considered these patients would be a rela-
tively unbiased comparison group. During the trial, it
was possible to treat all patients due to sufficient
plasma stocks, so we resorted to using a historic series
of patients as the control group. The historic patients
had not been assessed for their eligibility for plasma
treatment, and thus, it was not possible to apply the
same exclusion criteria. However, during the trial, very
few patients were excluded from plasma treatment
(most of whom died by the third day after diagnosis).
In the analyses, we adjusted for measured differences in
potential confounding factors, including a measure of
presenting viral load. However, in comparing patients
treated with plasma to the historic series, it was not
possible to be sure that all potential sources of residual
confounding had been eliminated, and this is an impor-
tant caveat in our findings.
In an important complementary analysis, we will
seek evidence of any relationship between the antibody
level in the donor plasma and the survival and change
in viral load in treated patients. These analyses do not
need historic data, and treatment with plasma with
high or low titers, which was not known at the time of
administration, would be expected to be close to
random.
Our experience demonstrates that rapidly designing
and conducting clinical trials in a humanitarian crisis
setting are possible. Substantial time was invested in
discussions with the field clinical team on how to
Table 2. (continued)
Possible source
of bias
Problem Analytical approach in the
analysis plan to reduce bias
Implications
Treatment bias Supportive care administration
could be variable over time.
Although the trial and historic
data are from the same Ebola
treatment center, managed by
the same organization over
time, it is not possible to
adequately measure or account
for variability in supportive care
provision in the analysis.
Residual bias may be present.
Receipt of additional
experimental treatments such as
Favipiravir would not allow
evaluation of convalescent
plasma with supportive care
versus supportive care alone.
Exclude patients who received
additional experimental
treatments.
Smaller sample size but more
appropriate analysis group.
PCR: polymerase chain reaction.
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prioritize, who to exclude from the trial and how to
standardize supportive care. During the inter-epidemic
period, such topics should be further discussed to reach
a consensus before the next outbreak. During an out-
break, early consultation and involvement of both aca-
demic and operational partners are indicated.
The Ebola_Tx protocol, standard operating proce-
dures, case report forms and data management system
with electronic case report forms, specifically developed
for the high-risk treatment center context,18 have now
been extensively field-tested and can be adapted for
other future outbreaks of hemorrhagic fever where con-
valescent plasma is a proposed treatment. It is unclear
whether randomization to treatments would be accep-
table to patients or healthcare workers in the future,
but preparedness for collecting standardized control
data from all treatment centers could be enhanced by
sharing field-tested materials between existing networks
(e.g. the International Severe Acute Respiratory and
Emerging Infection Consortium, https://isaric.tghn.org/)
so that they can be rapidly implemented from the onset
of any new outbreak.
The main outstanding challenge to all trials of treat-
ments for Ebola is the lack of standardized protocols
for harmonized and stable supportive care, which is
important irrespective of the study design chosen.
Standardized point of care tools could better inform
patient management and improve standardization.
High-level, patient-directed care with aggressive man-
agement of hypovolemia, electrolyte disturbances and
kidney injury, and including antivirals if shown to be
effective, might improve supportive care in future ther-
apeutic trials.19,20 In-depth anthropological studies
should also be conducted to gain a better understand-
ing on community acceptability of randomization dur-
ing outbreaks of diseases with high case fatality rates.
Conclusion
Although a randomized trial would have been metho-
dologically preferable, the Ebola_Tx trial represents a
valuable experience of an alternative design, developed
during an outbreak where randomization was not
acceptable. Due reflection and efforts were dedicated
on minimizing potential sources of bias in our compari-
son of mortality among patients receiving supportive
care with the addition of treatment with convalescent
plasma. We cannot exclude the possibility of residual
bias due to the lack of randomization and blinding in
the design. Having conducted the largest ever study of
convalescent plasma for Ebola disease, field-tested pro-
tocols and electronic data capture systems are now
available for high-risk emergency evaluation of such
treatment. Neutralizing antibody levels in donated
plasma will allow further consideration of the effect of
the treatment.
Conﬁrmed cases with  known 
outcome, age and cycle threshold 
values
Historic series 
N = 505
Trial series 
N = 113
Total deaths up to day two post 
diagnosis;
Deaths before enrolment could 
take place
Deaths aer enrolment before 
plasma could be given or clinically 
ineligible 
Primary end point: Follow-up 
between 3rd and 16th day post 
diagnosis
Secondary endpoint: day  30
Died
Possible survival status: 
- discharged cured by day 16
- sll admied 
As per period of 3rd to 16th
day post diagnosis
Died
Possible survival status: 
- discharged cured by day 16
- sll admied 
Addional follow-up by 
telephone to conﬁrm 
survival status
87 (17.2%)
Unknown
Unknown
19 (16.8%) 
12 (10.6%)
7 (6.2%)
Screening
Follow-up
Figure 2. Screening and application of the exclusion criterion of deaths up to 2 days after confirmation of Ebola virus disease
diagnosis.
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